BIOXCEL THERAPEUTICS INC. - COMMON STOCK

BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium

14 Feb 2022 17:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

09 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer

19 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Initiates Pivotal Phase 3 Program of BXCL501 for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

15 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders

01 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at the 2021 Jefferies London Healthcare Conference

11 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer

18 Oct 2021 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery and Development and Advances in Neuroscience Portfolio at Virtual R&D Day

23 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO

15 Sep 2021 18:06:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress

12 Sep 2021 18:05:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Host Virtual R&D Day on September 23, 2021

09 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights

10 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

19 Jul 2021 07:30:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock

23 Jun 2021 08:28:58 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Proposed Public Offering of Common Stock

22 Jun 2021 16:01:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Host Virtual Commercial Day on June 25, 2021

18 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

26 May 2021 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II

19 May 2021 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Presentations at the ISBD 2021 Global Annual Conference

11 May 2021 07:00:02 By Nasdaq GlobeNewswire